Surveillance of infectious complications associated with central venous access devices in children with haemophilia

被引:40
|
作者
Tarantino, MD
Lail, A
Donfield, SM
Lynn, H
Peddle, L
Hunsberger, S
Shapiro, AD
机构
[1] Univ Illinois, Comprehens Bleeding Disorders Ctr, Coll Med, Peoria, IL 61614 USA
[2] Rho Inc, Chapel Hill, NC USA
[3] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA
关键词
catheter-related infection; central venous catheter; haemophilia; inhibitor;
D O I
10.1046/j.1365-2516.2003.00793.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To analyse the risk factors for infection associated with central venous access device (CVAD) use in children with haemophilia. Methods: Risk factors for CVAD infection among patients with congenital haemophilia who had had a CVAD implanted at a single institution were evaluated utilizing the following variables: age at CVAD placement, age at end of study, number of days with a CVAD, percentage of lifetime with a CVAD, and history of inhibitor. Results: Fifty-nine patients had a total of 97 936 (median 1768 days per patient) CVAD days in the study period. The median age at CVAD placement was 2.7 years (range 0-14.0). Twenty-six (44%) patients reported CVAD infections during the study period from January 1993 to October 2000. Twenty-four patients had their CVAD replaced, 17 (71%) of whom reported having infections and seven (29%) of whom had a history of inhibitor. The strongest predictor for having any infections was inhibitor status (P = 0.16), although none of the risk factors had statistically significant effects. Among the 26 patients reporting infections, 42% had more than one CVAD-related infection. Seven patients had multiple infections involving the same organism. The mean rate of infection was 0.45 per 1000 catheter days, with a 95% confidence interval of 0.33-0.60. Those with a history of inhibitor had an infection rate of 0.66 compared with 0.38 per 1000 catheter days (P = 0.09) for those without a history of inhibitor. Patients who were older ( greater than the median age of 2.7) at CVAD placement had a lower rate of infection (0.29 vs. 0.65, P < 0.01) compared with those ≤2.7 years. Adjustment for inhibitor status had little impact on these results. For the group as a whole, the median time to first infection was 1977 days from CVAD placement. Patients who were older at CVAD placement or study exit had lower relative hazards of infection (P = 0.05 and P = 0.09 respectively), while those who had inhibitors had a higher but not statistically significant relative hazard of 1.88 (P = 0.13). Conclusions: These data reveal that while considerable numbers of patients develop CVAD-related infection, the interval between catheter placement and infection can be quite long. In addition, the earlier in life a CVAD is placed, the higher the risk of infectious complications, as evidenced by the tendency towards a higher infection rate. Measures to prevent CVAD-related infection might be focused on very young patients who appear to be at higher risk.
引用
下载
收藏
页码:588 / 592
页数:5
相关论文
共 50 条
  • [21] Additional data on the morbidity of central venous access devices in patients with haemophilia
    Geraghty, S
    Kleinert, D
    HAEMOPHILIA, 1998, 4 (01) : 66 - 66
  • [22] Incidence and risk factors of complications during central venous access devices removal in children
    Liu, Sue
    Nataraja, Ramesh M.
    Lynch, Amiria
    Ferguson, Peter
    Pacilli, Maurizio
    JOURNAL OF VASCULAR ACCESS, 2024,
  • [23] Skin Complications Associated With Pediatric Central Venous Access Devices: Prevalence, Incidence, and Risk
    Ullman, Amanda J.
    Kleidon, Tricia M.
    Turner, Karen
    Gibson, Victoria
    Dean, Anna
    Cattanach, Paula
    Pitt, Colleen
    Woosley, Julieta
    Marsh, Nicole
    Gavin, Nicole
    Takashima, Mari
    Rickard, Claire M.
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2019, 36 (05) : 343 - 351
  • [24] Impact of insertion site on complications in central venous access devices
    Sara A. Mansfield
    Jessica Staszak
    Andrew J. Murphy
    Lindsay Talbot
    Abdelhafeez Abdelhafeez
    Hasmukh Prajapati
    Robert Gold
    Vinod Maller
    Kimberly Proctor
    Andrew M. Davidoff
    Regan F. Williams
    Pediatric Surgery International, 39
  • [25] Utilization and Complications of Central Venous Access Devices in Oncology Patients
    Akhtar, Narmeen
    Lee, Linda
    CURRENT ONCOLOGY, 2021, 28 (01) : 367 - 377
  • [26] Impact of insertion site on complications in central venous access devices
    Mansfield, Sara A.
    Staszak, Jessica
    Murphy, Andrew J.
    Talbot, Lindsay
    Abdelhafeez, Abdelhafeez
    Prajapati, Hasmukh
    Gold, Robert
    Maller, Vinod
    Proctor, Kimberly
    Davidoff, Andrew M.
    Williams, Regan F.
    PEDIATRIC SURGERY INTERNATIONAL, 2023, 39 (01)
  • [27] A prospective clinical trial of implantable central venous access in children with haemophilia
    Santagostino, E
    Gringeri, A
    Muca-Perja, M
    Mannucci, PM
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (05) : 1224 - 1228
  • [28] Central venous access in children: indications, devices, and risks
    Ares, Guillermo
    Hunter, Catherine J.
    CURRENT OPINION IN PEDIATRICS, 2017, 29 (03) : 340 - 346
  • [29] Central venous access devices in children with hemophilia: an update
    Blanchette, VS
    AlMusa, A
    Stain, AM
    Ingram, J
    Fille, RM
    BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 : S11 - S14
  • [30] Infectious Complications of Peripherally Inserted Central Venous Catheters in Children
    Levy, Itzhak
    Bendet, Moshe
    Samra, Zmira
    Shalit, Itamar
    Katz, Jacob
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (05) : 426 - 429